Tredje AP fonden Sells 22,900 Shares of Johnson & Johnson (NYSE:JNJ)

Tredje AP fonden lowered its position in Johnson & Johnson (NYSE:JNJ) by 13.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 152,622 shares of the company’s stock after selling 22,900 shares during the period. Tredje AP fonden’s holdings in Johnson & Johnson were worth $22,307,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Meiji Yasuda Asset Management Co Ltd. grew its holdings in Johnson & Johnson by 6.6% in the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 135,526 shares of the company’s stock worth $19,808,000 after purchasing an additional 8,408 shares during the last quarter. Argent Trust Co increased its position in Johnson & Johnson by 0.5% during the 2nd quarter. Argent Trust Co now owns 189,595 shares of the company’s stock valued at $27,711,000 after buying an additional 963 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its stake in Johnson & Johnson by 3.9% in the second quarter. Mercer Global Advisors Inc. ADV now owns 695,805 shares of the company’s stock valued at $92,799,000 after buying an additional 26,174 shares during the last quarter. E Fund Management Co. Ltd. grew its stake in shares of Johnson & Johnson by 12.2% during the second quarter. E Fund Management Co. Ltd. now owns 16,173 shares of the company’s stock worth $2,364,000 after acquiring an additional 1,755 shares during the last quarter. Finally, Financial & Tax Architects LLC increased its holdings in shares of Johnson & Johnson by 11.9% during the second quarter. Financial & Tax Architects LLC now owns 39,362 shares of the company’s stock valued at $5,753,000 after acquiring an additional 4,189 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $167.07 on Wednesday. The firm has a market cap of $402.08 billion, a PE ratio of 10.42, a P/E/G ratio of 2.71 and a beta of 0.53. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The business has a 50-day moving average price of $160.38 and a 200 day moving average price of $154.01.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. During the same period in the previous year, the business earned $2.80 earnings per share. The business’s revenue was up 4.3% compared to the same quarter last year. Sell-side analysts predict that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were given a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 2.97%. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Analysts Set New Price Targets

JNJ has been the topic of a number of recent analyst reports. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Morgan Stanley lifted their price target on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 18th. Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $160.00 to $150.00 in a report on Tuesday, July 23rd. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Finally, TD Cowen reduced their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, July 18th. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.21.

Insider Buying and Selling

In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.